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Topical tacrolimus with Colgate Oraguard‐B paste for
managing oral lichen planus: A prospective clinical study
among northern Indian subjects
Gupta Vikas*, Singh Abhishek, Mengi Arvind
Email: drabhisheksingh@gmcmewat.ac.in

Abstract
Background: As of today, no standard treatment protocol nor preventive measures either exists for oral lichen
planus. The present investigation aimed to test topical 0.1% tacrolimus as compared to Colgate Oraguard-B
paste for managing lesions of oral lichen planus. Methods: It was a hospital-based prospective study with
histopathologically confirmed 135 patients of oral lichen planus as subjects, which were provided with 0.1%
tacrolimus ointment with Colgate Oraguard-B paste. The duration of treatment ranged from three to four
months, with a follow-up of till two years. Study subjects were followed up every fifteen days. The results were
expressed using mean and standard deviation. Wilcoxon signed-rank test was used to test the significance.
Results: At the time of the first visit, pain intensity was the worst (visual analogue scale (VAS) scores 9-10).
Scores came down to 1-2 (significant reduction in pain) after two months of therapy. Mean values of pre and
post VAS scores in the domain of erosive type of oral lichen planus were 9.47±1.22 and 2.84±0.27. Differences
in pre and post VAS scores were found to be significant for oral lichen planus. Conclusions: Subjects reported
a significant decrease in pain by the intervention (topical 0.1% tacrolimus ointment with Oraguard-B past) in a
short period. This provided us with a new line of management with promising results for managing oral lichen
planus.
Key words: Follow up, hospital-based, visual analogue scale

Introduction
The lichen planus (LP) is an autoimmune disorder
that manifests orally and dermally. In general, the
overall prevalence of LP is less than three % (0.5 %
to 2.6 %), and on a similar note about 2.6 % of Indians
having oral lichen planus (OLP).1 OLP is a condition
having the potential of malignant transformation
and among the Indian population, the malignancy
transforming rate ranges between 0.5 % to 2.0 %.2,
3
OLP most commonly affects the tongue, gingiva,
and buccal mucosa. World Health Organisation has
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tabulated OLP amongst the conditions of potentially
malignant.4 The commonly occurring malignancy
from progressive transforming changes of OLP is
oral squamous cell carcinoma (SCC).5
Exact underlying etiology is not clear, however, it
is thought that stress, allergy, immunity, diabetes,
and hypertension might act as a precursor for LP
occurrence.6 At the molecular level, proposed and
accepted pathogenesis are activation of matrix
metalloproteinases (MMP), deregulation of mast
cells, and killing of keratinocytes from T cell (CD8+
cytotoxic).7 Patients commonly report relapse and
remissions, thus we must aim to deal with painful
conditions, minimizing the risk of oral malignancy,
and keep better oral hygiene.8
As of today, no standard treatment protocol,
nor preventive measures either exists for OLP.
Corticosteroids are being widely used for OLP
management because corticosteroid modifies cellmediated immune activity. It is time to test another
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alternative medicine for managing OLP. Tacrolimus
inhibits mediators released from basophil and mast
cell, along with that it stops activities for calcineurin
phosphatase enzymes, which hinder formation
and secretions of IL-2, finally leads to inhibit the
multiplication of T cells. Colgate Oraguard-B
paste has a property for providing faster and earlier
relieving of pain due to its mucoadhesive nature,
which acts as a protective barrier.9 So, the present
study was conducted to investigate the efficacy
of topical 0.1% tacrolimus along with Colgate
Oraguard-B paste in managing OLP lesions among
north Indian subjects.
Material and Methods
The present study was prospective and was carried
out under the aegis of the department of dentistry
in a tertiary care health centre of northern India.
The study population were the patients with lesions
of OLP and visiting the dentistry department for
seeking care. Subjects were included in the study
only after receiving confirmation reports from the
histopathology department and after obtaining
written informed consent. Patients taking medicines
for other systemic disorders were excluded from this
study. In the same way, subjects giving a history of
kidney disease, disease of liver and gallbladder, or
uncontrolled hypertension were also not included. A
structured format was used to collect demographic
data such as age, sex, relevant medical history and
habits, duration of OLP, previous treatment history,
the size of the lesion including its remission/size
reduction, and scores for VAS. Clinical photographs
of the lesion were also captured.

vernacular language that VAS has 0-10 cm line and
were instructed to mark their experience of pain
symptoms between that line where 0 cm and 10 cm
denoted “no pain” and “worst pain” respectively.
Different forms of OLPs were recorded among
study subjects viz. erosive, atrophic, reticular, and
mixed. An oral intervention was given in the form of
0.1% tacrolimus ointment with Colgate Oraguard-B
paste (500 mg of tacrolimus powder was mixed with
300 g Oraguard-B paste). The study subjects were
instructed to apply the intervention sparingly over
the lesions thrice a day (after meals and not to eat or
rinse for at least 45 min after its application) until it
gets resolved. Study subjects were followed up every
fifteen days to assess the response of intervention.
The total follow up period for the present study was
two years including treatment duration ranging
between three to four months.

The reduction in size of LP lesion was defined into
six categories including no lesion; white striae/s
only; white striae/s with erosion/s (<1 cm2 or >1
cm2); and white striae/s with ulceration/s (<1 cm2
or >1 cm2).

Conduction of study initiated after getting clearance
from the Institutional Ethics Committee (Approval
letter number: SHKM/ME-I/2015/25). All the
proforma were manually checked for completeness
and data were entered in the MS Excel spreadsheet,
coded appropriately, and later cleaned for any possible
errors. The analysis was carried out using IBM
SPSS Statistics for Windows, Version 21.0 (IBM
Corp. Armonk, NY, USA). The continuous data were
presented as mean and standard deviation, whereas
categorical data were presented as percentages (%).
Wilcoxon signed-rank test was conducted to capture
the difference in the VAS scores before and after the
intervention. All tests were performed at a 5% level
of significance; thus, an association was significant if
the p-value was less than 0.05.

The assessment and quantification of pain
symptoms among study subjects were done using
VAS. Worldwide, VAS rating is an accepted measure
to assess the pain among adults. There are two
continuous scale lines in VAS, i.e. horizontal visual
analogue scale (HVAS) and vertical visual analogue
scale (VVAS). In general, each scale line is 10 cm in
length, based on two verbally fixed extreme forms
for each symptom. Study subjects were explained in

Results
The present study included 135 subjects with a
histopathologically confirmed diagnosis of OLP.
The mean age of study subjects was 41.25±3.4
years. Females outnumbered male subjects. At the
time of the first visit, pain intensity was worst (VAS
scores 9-10). Scores came down to 1-2 (significant
reduction in pain) after two months of therapy.
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Table 1: VAS scoring of different forms of OLP among study
subjects
Forms of
OLP

Pre-VAS
Mean

SD

Erosive
9.47
1.22
Atrophic
7.90
0.74
Reticular
4.29
0.38
Mixed
7.42
0.95
*Wilcoxon signed ranks test

Post-VAS
Mean

SD

2.84
1.80
1.45
3.28

0.27
0.18
0.40
0.53

P-value*
<0.001
<0.001
<0.001
<0.001

Mean values of pre and post VAS scores in the
domain of erosive type of OLP were 9.47±1.22
and 2.84±0.27. Mean pre and post VAS scores
for atrophic forms of OLP were 7.90±0.74 and
1.80±0.18. In the same way, mean values of pre
and post VAS scores for reticular and mixed forms
of OLP were 4.29±0.38, 1.45±0.40 and 7.42±0.95,
3.28±0.53 respectively. Differences in pre and post
VAS scores were found to be statistically significant
among all forms of OLP (Table 1).
Complete remission/size reduction of the lesion
was noted down in sixty-five subjects (≈48%) in
18-24 months of tacrolimus therapy and partial
remission/incomplete size reduction of lesions was
seen in fifty-seven subjects (≈42%) in 24-30 months
of therapy (p<0.05) (Table 2).
Table 2: Response to tacrolimus therapy for various time
duration among study subjects
Response to therapy
Duration of
Percentage
tacrolimus
of group
therapy
(approximately)*
No response/
4-6 months
10% (n=13)
recurrence
Partial remission/
18-24 months
42% (n=57)
incomplete size
reduction of lesion
Complete remission/
12-18 months
48% (n=65)
size reduction of lesion
(*Level of significance; p<0.05)

No adverse effects including the development
of candida infection were reported by any of the
subjects under study. Moreover, the burning
sensation diminished spontaneously on subsequent
applications and it was present in only five patients.
Discussion
Currently, OLP is clinically managed via
corticosteroids (either orally or systemically).
The second line of
treatments includes
retinoids; hydroxychloroquine; mycophenolate
mofetil; azathioprines; UV phototherapies; and
pimecrolimus.9
18
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Topical tacrolimus is a new management
modality that acts as an immunomodulator. It is a
noncorticosteroidal agent. Pharmacologically it is
a calcineurin inhibitor that has been approved for
management of atopic dermatitis. This molecule
comes from the macrolide family that is multifold
more potent than cyclosporine with better
percutaneous absorption.10
On analysis, the mean age (in years) including
standard deviation of present study subjects was
reported as 41.25±3.4 years. Females outnumbered
male subjects. These findings were comparable with
others.11, 12
We observed that mean values of pre and post VAS
scores in the domain of erosive type of OLP were
9.47±1.22 and 2.84±0.27. These observations are
comparable with another study from Maharashtra,
where the completely resolved or distinctly reduced
lesions after the intervention was captured among
nearly half of study subjects (47.3% or 43.3%
respectively) and only one-tenth of study subjects
(9.3%) had complete remission.13
Comparable results were also obtained by Nishu
Vakil, et al.,14 who observed that mean values of pre
and post VAS for the atrophic form or erosive form
of OLP were 7.82±0.56, 1.71±0.22 or 9.35±1.02,
2.96±0.24 respectively. Similarly, mean pre and post
VAS scores for reticular and mixed forms of OLP
were 4.16±0.44, 1.32±0.34 and 7.36±0.59, 3.33±0.48
respectively. Statistically significant results were
obtained between pre and post-treatment values on
the VAS among all forms of OLP.
Azizi, et al.,15 estimated the efficacies of the two
different interventions for treating OLP (erosive
form) where one group received the adcortyl
(ointment, topical) and other group received the
tacrolimus (ointment, topical) and it was revealed that
nearly half of subjects have shown an improvement
in both symptoms (57.3%) and signs scores (55.8%),
but results for this study might not be comparable
with present study due to inclusion of subjects with
the only erosive form of OLP and application of
some other score systems for symptoms, along with
the short duration of the study (four weeks only) in
that study. Giustina, et al.,16 proved the efficacy of
isotretinoin (0.1%, topical gel) as applying it over the
lesion for two times a day continuously for nearly

Manipal Journal of Medical Sciences | June 2020 | Volume 5 | Issue 1

3

Manipal Journal of Medical Sciences, Vol. 5 [2021], Iss. 1, Art. 2
Gupta V et al: Tacrolimus with Colgate Oraguard‐B paste for oral lichen planus

wo months (eight weeks), effectively improved the
symptom among the majority of subjects (90.0%)
with OLP.
In a clinical study, Raj AC, et al.,17 estimated the
efficacy of the dapsone intervention for treating OLP
(resistant and erosive form) and it was revealed that
nearly half of subjects have shown an improvement
in both symptoms scores of 0 (54.4%) and 1 (45.6%)
while about four-fifth of subjects (83.3%) had shown
improvement in signs scores of 0.16.
Sahebjamee M, et al., 18 estimated the efficacies of
the two different interventions for treating OLP
where one group received the retinoic acid (topical,
0.05%) and other group received the triamcinolone
acetonide (topical, 0.1%) and it was revealed that
there was a statistically significant difference in
efficacies of two interventions for the treatment
of different forms of OLP such as atrophic form
(p<0.05) and erosive form (p<0.05) and retinoic acid
was proven to be more effective.
To conclude, study subjects after intervention with
topical tacrolimus (0.1%) and Oraguard-B paste
reported significant improvement in pain within
the short reference of time. No adverse effect was
reported even after a follow-up period of two years.
This provided us with a new line of management
with promising results. Randomized-controlled
trials are warranted to validate the results of this
study.
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